

## Corrigendum to: The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients

Aesthetic Surgery Journal  
2021, Vol 41(12) 1494–1495  
© 2021 The Aesthetic Society.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

[www.aestheticsurgeryjournal.com](http://www.aestheticsurgeryjournal.com)

**OXFORD**  
UNIVERSITY PRESS

Joely Kaufman-Janette, MD; Rui L. Avelar, MD; Brian S. Biesman, MD; Zoe Diana Draelos, MD; John E. Gross, MD, FACS; Derek H. Jones, MD; Mary P. Lupo, MD; Corey S. Maas, MD; Joel Schlessinger, MD; Ava Teresa Shamban, MD; Hema Sundaram, MD, FAAD; Susan H. Weinkle, MD; and Vernon L. Young, MD

In the article “The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients” by Kaufman-Janette et al in *Aesthet Surg J*, sjaa383, <https://doi.org/10.1093/asj/sjaa383>, errors were noted in co-author Joel Schlessinger’s name and disclosure statement. A corrigendum is being published to address the following changes that have subsequently been corrected:

In the author list and affiliations, co-author Joel Schlessinger’s full name should read: “Joel Schlessinger,” rather than how it previously appeared.

In the Disclosure section, the following text should read: “Dr Schlessinger is an investor and has served on the advisory board for Evolus; he is also a shareholder of AbbVie, and has served as a researcher for Merz, Galderma, Allergan/AbbVie and Croma Pharma,” rather than how it previously appeared.

DOI: 10.1093/asj/sjab229

---

## Corrigendum to: The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients

Z. Paul Lorenc, MD, FACS; Jeffrey M. Adelglass, MD, FACS; Rui L. Avelar, MD; Leslie Baumann, MD; Kenneth R. Beer, MD; Joel L. Cohen, MD; Sue Ellen Cox, MD; Steven H. Dayan, MD; Jeffrey S. Dover, MD; Jeanine B. Downie, MD; Zoe Diana Draelos, MD; Mitchel P. Goldman, MD; John E. Gross, MD, FACS; John H. Joseph, MD; Joely Kaufman-Janette, MD; Ronald L. Moy, MD; Mark Nestor, MD; Joel Schlessinger, MD; Stacy R. Smith, MD; and Robert A. Weiss, MD